World Health Organization site
Skip Navigation Links

Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: ClinicalTrials.gov
Last refreshed on: 3 October 2023
Main ID:  NCT02760368
Date of registration: 29/04/2016
Prospective Registration: Yes
Primary sponsor: R-Pharm International, LLC
Public title: Evaluation of the Effectiveness and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease CREDO 1
Scientific title: A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate Therapy
Date of first enrolment: May 19, 2016
Target sample size: 428
Recruitment status: Completed
URL:  https://clinicaltrials.gov/ct2/show/NCT02760368
Study type:  Interventional
Study design:  Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator).  
Phase:  Phase 3
Countries of recruitment
Belarus Bulgaria Russian Federation Turkey
Contacts
Name:     Mikhail Samsonov
Address: 
Telephone:
Email:
Affiliation:  R-Pharm
Key inclusion & exclusion criteria

Inclusion Criteria:

Subjects may be enrolled in the study only if they meet all of the following criteria:

- Subjects willing and able to sign informed consent

- Subjects must have a diagnosis of adult onset RA classified by ACR/EULAR 2010 revised
classification criteria for RA for at least 12 weeks prior to Screening.

- Inadequate response to treatment with MTX for at least 12 weeks prior to Screening at
a dose of 15 to 25 mg/week (or =10 mg/week if intolerant to higher doses).

- The dose and means of administering MTX must have been stable for at least 6
weeks prior to Screening.

- Subjects must be willing to take folic acid or equivalent throughout the study

- Subjects must have moderately to severely active RA disease as defined by all of the
following:

- =6 tender joints (68 joint count) at Screening and baseline; and

- =6 swollen joints (66 joint count) at Screening and baseline; and

- CRP above ULN at Screening based on the central laboratory results.

Exclusion Criteria:

- Diagnosis of any other inflammatory arthritis or systemic rheumatic disease (e.g.,
gout, psoriatic or reactive arthritis, Crohn's disease, Lyme disease, juvenile
idiopathic arthritis, or systemic lupus erythematosus). However, subjects could have
secondary Sjogren's syndrome or hypothyroidism

- Subjects who were Steinbrocker class IV functional capacity (incapacitated, largely or
wholly bed-ridden or confined to a wheelchair, with little or no self-care)

- Prior exposure to any licensed or investigational compound directly or indirectly
targeting IL-6 or IL-6R (including tofacitinib or other Janus kinases and spleen
tyrosine kinase [SYK] inhibitors)

- Prior treatment with cell-depleting therapies, including anti-CD20 or investigational
agents (e.g., CAMPATH, anti-CD4, anti-CD5, anti-CD3, and anti-CD19)

- Prior use of bDMARDs, with the following exception:

• Subjects who discontinued TNFi therapy due to a reason other than lack of efficacy
were allowed to enter the study (TNFi therapy was not to be discontinued to facilitate
a subject's participation in the study but should instead have been previously
discontinued as part of a subject's medical management of RA). The use of TNFi therapy
within the following windows prior to baseline was exclusionary:

1. 4 weeks for etanercept

2. 8 weeks for infliximab

3. 10 weeks for adalimumab, certolizumab, and golimumab

- Use of parenteral and/or intra-articular glucocorticoids within 4 weeks prior to
baseline

- Use of oral glucocorticoids greater than 10 mg/day prednisone (or equivalent), or
change in dosage within 2 weeks prior to baseline

- Prior documented history of no response to hydroxychloroquine and sulfasalazine

- Prior use of cDMARDs (other than MTX) within the following windows prior to baseline
(cDMARDs were not to be discontinued to facilitate a subject's participation in the
study, but should instead have been previously discontinued as part of a subject's
medical management of RA):

1. 4 weeks for sulfasalazine, azathioprine, cyclosporine, hydroxychloroquine,
chloroquine, gold, penicillamine, minocycline, or doxycycline

2. 12 weeks for leflunomide unless the subject has completed the following
elimination procedure at least 4 weeks prior to baseline: Cholestyramine at a
dosage of 8 grams 3 times daily for at least 24 hours, or activated charcoal at a
dosage of 50 grams 4 times daily for at least 24 hours

3. 24 weeks for cyclophosphamide

- Vaccination with live vaccines in the 6 weeks prior to baseline or planned vaccination
with live vaccines during the study

- Participation in any other investigational drug study within 30 days or 5 times the
terminal half-life of the investigational drug, whichever is longer, prior to baseline

- Other treatments for RA (e.g., Prosorba Device/Column) within 6 months prior to
baseline

- Use of intra-articular hyaluronic acid injections within 4 weeks prior to baseline

- Use of non-steroidal anti-inflammatory drugs (NSAIDs) on unstable dose or switching of
NSAIDs within 2 weeks prior to baseline

- Previous participation in this study (randomized) or another study of OKZ

- Subjects with acute or chronic viral hepatitis B or C infection as detected by blood
tests at Screening (e.g., positive for hepatitis B surface antigen [HBsAg], total
hepatitis B core antibody [anti-HBc], or hepatitis C virus antibody [HCV Ab])

a. Subjects who were positive for hepatitis B surface antibody (anti-HBs), but
negative for HBsAg and anti-HBc, were eligible

- Subjects with HIV infection

- Subjects with:

1. Suspected or confirmed current active TB disease or a history of active TB
disease

2. Close contact (i.e., sharing the same household or other enclosed environment,
such as a social gathering place, workplace, or facility, for extended periods
during the day) with an individual with active TB within 1.5 years prior to
Screening.

- Concurrent malignancy or a history of malignancy within the last 5 years (with the
exception of successfully treated carcinoma in situ of the cervix and successfully
treated basal cell carcinoma and squamous cell carcinoma not less than 1 year prior to
Screening [and no more than 3 excised skin cancers within the last 5 years prior to
Screening])

- Subjects with any infection requiring oral antibiotic or antiviral therapy in the 2
weeks prior to Screening or at baseline, injectable anti-infective therapy in the last
4 weeks prior to baseline, or serious or recurrent infection with a history of
hospitalization in the 6 months prior to baseline

- Subjects with evidence of disseminated herpes zoster infection, zoster encephalitis,
meningitis, or other non-self-limited herpes zoster infections in the 6 months prior
to baseline

- Subjects with planned surgery during the study or surgery =4 weeks prior to Screening
and from which the subject had not fully recovered, as judged by the Investigator

- Subjects with diverticulitis or other symptomatic GI conditions that might predispose
the subject to perforations, including subjects with a history of such predisposing
conditions (e.g., diverticulitis, GI perforation, or ulcerative colitis)

- Pre-existing central nervous system demyelinating disorders (e.g., multiple scle



Age minimum: 18 Years
Age maximum: N/A
Gender: All
Health Condition(s) or Problem(s) studied
Rheumatoid Arthritis
Intervention(s)
Drug: Placebo
Drug: Olokizumab
Primary Outcome(s)
Percentage of Subjects Achieving American College of Rheumatology 20% (ACR20) Response [Time Frame: at Week 12]
Secondary Outcome(s)
Percentage of Subjects Achieving American College of Rheumatology 50% (ACR50) Response [Time Frame: at Week 24]
Percentage of Subjects With Clinical Disease Activity Index (CDAI) = 2.8 (Remission) [Time Frame: at Week 24]
Percentage of Subjects Achieving Low Disease Activity [Time Frame: at Week 12]
Improvement of Physical Ability From Baseline to Week 12, as Measured by the Health Assessment Questionnaire Disability Index (HAQ-DI) [Time Frame: Baseline to Week 12]
Secondary ID(s)
2014-004719-36
CL04041022
Source(s) of Monetary Support
Please refer to primary and secondary sponsors
Secondary Sponsor(s)
Mene Research
OCT Clinical Trials
Quintiles, Inc.
Ethics review
Results
Results available: Yes
Date Posted: 30/10/2020
Date Completed:
URL: https://clinicaltrials.gov/ct2/show/results/NCT02760368
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history